Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review

PharmacoEconomics

Volumn 33, Issue 9, 2015, Pages 939-955

  Laurence, Yoko V ^a   Griffiths, Ulla K ^a   Vassall, Anna ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DAY HOSPITAL; DRUG COST; DRUG SUSCEPTIBLE TUBERCULOSIS; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; OUTPATIENT CARE; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; TRAFFIC AND TRANSPORT; TUBERCULOSIS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICE; PUBLIC HEALTH; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; HEALTH SERVICES; HUMANS; NATIONAL HEALTH PROGRAMS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84941023489     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-015-0279-6     Document Type: Review

References (115)

1. WHO. The End TB Strategy: Global strategy and targets for tuberculosis prevention, care and control after 2015. In: World Health Organisation, editor. WHO Global Tuberculosis Report. Geneva: WHO; 2014. p. 23.
2. Fryatt RJ. Review of published cost-effectiveness studies on tuberculosis treatment programmes. Int J Tuberc Lung Dis. 1997;1(2):101–9.
3. Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg. 2004;71(2 Suppl):147–55.
4. Verdier JE, et al. A systematic review of economic evaluation studies of tuberculosis control in high-income countries. Int J Tuberc Lung Dis. 2011;15(12):1587–98.
5. Ukwaja KN, et al. The economic burden of tuberculosis care for patients and households in Africa: a systematic review. Int J Tuberc Lung Dis. 2012;16(6):733–9.
6. Barter DM, et al. Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa—a systematic review. BMC Public Health. 2012;12:980.
7. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63–80.
8. Diel R, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43(2):554–65.
9. Tanimura T, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763–75.
10. Google. Google translate. 2015 17 February 2015; electronic translation software. Available from: https://translate.google.co.uk/. Accessed 7 Feb 2015.
11. CRD. Systematic Reviews: CRD’s guidance for undertaking systematic reviews in health care. In: Centre for reviews and dissemination, editor. CRD. York: University of York; 2009.
12. Shemilt I, et al. Chapter 15: incorporating economics evidence. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: The Cochrane Collaboration; 2011.
13. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31(7):537–49.
14. Steffen R, et al. Patients’ costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One. 2010;5(11):e14014.
15. OANDA. Historical exchange rates. 2015: http://www.oanda.com/currency/historical-rates/. Accessed 9 Mar 2015.
16. International monetary fund, data and statistics. 2015: http://www.imf.org/external/data.htm. Accessed 9 Mar 2015.
17. World Bank. How we classify countries. 2015; Available from: http://data.worldbank.org/about/country-and-lending-groups. Accessed 9 Mar 2015.
18. Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–50.
19. Mauch V. The tool to estimate patients’ costs, in http://www.stoptb.org/wg/dots_expansion/tbandpoverty/assets/documents/Tool%20to%20estimate%20Patients’%20Costs.pdf. 2008, KNVI Tuberculosis Foundation. Accessed 31 Oct 2014.
20. Boyd KA, et al. Power and sample size for cost-effectiveness analysis: fFN neonatal screening. Contemp Clin Trials. 2011;32(6):893–901.
21. Hollingworth W, et al. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter? Clin Trials. 2013;10(1):43–53.
22. Mihaylova B, et al. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916.
23. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax. 2000;55(11):962–3.
24. Diel R, et al. Tuberculosis: cost of illness in Germany. Eur Respir J. 2012;40(1):143–51.
25. Pooran A, et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8(1):e54587.
26. Dick J, Henchie S. A cost analysis of the tuberculosis control programme in Elsies River, Cape Town. S Afr Med J. 1998;88(3 Suppl):380–3.
27. Drummond M, Schulper JS, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
28. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8(8):1012–6.
29. Kik SV, et al. Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands. BMC public health. 2009;9:283.
30. Jacobs B, et al. Cost-effectiveness analysis of the russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia. Int J Tuberc Lung Dis. 2002;6(5):396–405.
31. Kang YA, et al. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology. 2006;11(6):793–8.
32. Pantoja A, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis. 2009;13(6):698–704.
33. Weis SE, et al. Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: a comparative analysis. Int J Tuberc Lung Dis. 1999;3(11):976–84.
34. Floyd K, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ. 2006;84(6):437–45.
35. Vassall A, et al. Reforming tuberculosis control in Ukraine: results of pilot projects and implications for the national scale-up of DOTS. Health Policy Plan. 2009;24(1):55–62.
36. Floyd K, et al. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S29–37.
37. Okello D, et al. Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S72–9.
38. Burman WJ, et al. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 1997;112(1):63–70.
39. Burns AD, Harrison AC. Costs of investigating and managing non-residents with possible tuberculosis: New Zealand experience of an international problem. Respirology. 2007;12(2):262–6.
40. Atun RA, et al. Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis. Health Policy Plan. 2006;21(5):353–64.
41. Miller TL, et al. The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. Cost Eff Resour Alloc. 2013;11(1):9.
42. Fairall L, et al. Cost-effectiveness of educational outreach to primary care nurses to increase tuberculosis case detection and improve respiratory care: economic evaluation alongside a randomised trial. Trop Med Int Health. 2010;15(3):277–86.
43. Masobe P, Lee T, Price M. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients—a least-cost analysis. S Afr Med J. 1995;85(2):75–81.
44. Cusmano LG, et al. Study of the intangible costs and impact of the household component in the social cost of tuberculosis. Revista Argentina de Salud Publica. 2009;1(1):18–23.
45. Moalosi G, et al. Cost-effectiveness of home-based care versus hospital care for chronically ill tuberculosis patients, Francistown, Botswana. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S80–5.
46. Vassall A, et al. Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria. Int J Tuberc Lung Dis. 2002;6(12):1083–90.
47. Khan MA, et al. Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment. Health Policy Plan. 2002;17(2):178–86.
48. Bocchino M, et al. Cost determinants of tuberculosis management in a low-prevalence country. Int J Tuberc Lung Dis. 2006;10(2):146–52.
49. Wilkinson D, Floyd K, Gilks CF. Costs and cost-effectiveness of alternative tuberculosis management strategies in South Africa—implications for policy. S Afr Med J. 1997;87(4):451–5.
50. Saunderson PR. An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda. Soc Sci Med. 1995;40(9):1203–12.
51. Eralp MN, et al. Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice. BMJ Open. 2012;2(2):e000630.
52. Miller TL, et al. The societal cost of tuberculosis: Tarrant County, Texas, 2002. Ann Epidemiol. 2010;20(1):1–7.
53. Peralta Perez M, et al. Costo del programma nacional de control de la tuberculosis. Centro provincial de higiene y epidemiologia de ciudad de La Habana, 2002. Rev Cuba Med Trop. 2006;58(1):63–7.
54. El-Sony AI. The cost to health services of human immunodeficiency virus (HIV) co-infection among tuberculosis patients in Sudan. Health Policy. 2006;75(3):272–9.
55. Floyd K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J. 2012;40(1):133–42.
56. Marks SM, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20(5):812–21.
57. Schnippel K, et al. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health. 2013;18(1):109–16.
58. Tupasi TE, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3(9):e352.
59. Pichenda K, et al. Non-hospital DOT and early diagnosis of tuberculosis reduce costs while achieving treatment success. Int J Tuberc Lung Dis. 2012;16(6):828–34.
60. Xu Q, Jin SG, Zhang LX. Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing. Biomed Environ Sci. 2000;13(4):307–13.
61. Kamolratanakul P, et al. Cost analysis of different types of tuberculosis patient at tuberculosis centers in Thailand. Southeast Asian J Trop Med Public Health. 2002;33(2):321–30.
62. Suarez PG, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359(9322):1980–9.
63. Pan HQ, et al. Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China. Int J Tuberc Lung Dis. 2013;17(12):1575–1580+i.
64. Jacquet V, et al. Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti. BMC Public Health. 2006;6:209.
65. Montes-Santiago J, et al. Tuberculosis-related hospitalization in Spain: a cost analysis. Enferm Infec Microbiol Clin. 2010;28(6):358–61.
66. Nganda B, et al. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S14–20.
67. Wyss K, Kilima P, Lorenz N. Costs of tuberculosis for households and health care providers in Dar es Salaam, Tanzania. Trop Med Int Health. 2001;6(1):60–8.
68. Mauch V, et al. Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents. Int J Tuberc Lung Dis. 2013;17(3):381–7.
69. Aye R, et al. Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan. BMC Public Health. 2010;10:18.
70. Jackson S, et al. Poverty and the economic effects of TB in rural China. Int J Tuberc Lung Dis. 2006;10(10):1104–10.
71. Yitayal M, et al. Assessment of cost of tuberculosis to patients and their families: a cross-sectional study at Addet Health Center, Yilmana Densa District, Amhara National Regional State. Ethiop Med J. 2014;Suppl 1:23–30.
72. Elamin EI, et al. Cost of illness of tuberculosis in Penang, Malaysia. Pharm World Sci. 2008;30(3):281–6.
73. Islam MA, et al. Cost-effectiveness of community health workers in tuberculosis control in Bangladesh. Bull World Health Organ. 2002;80(6):445–50.
74. Vassall A, et al. Patient costs of accessing collaborative tuberculosis and human immunodeficiency virus interventions in Ethiopia. Int J Tuberc Lung Dis. 2010;14(5):604–10.
75. Gospodarevskaya E, et al. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: The potential of shorter regimens. Int J Tuberc Lung Dis. 2014;18(7):810–817+i–ii.
76. Migliori GB, et al. Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. Ivanovo Tuberculosis Project Study Group. Bull World Health Organ. 1998;76(5):475–83.
77. Sawert H, et al. Costs and benefits of improving tuberculosis control: the case of Thailand. Soc Sci Med. 1997;44(12):1805–16.
78. Migliori GB, et al. Cost-comparison of different management policies for tuberculosis patients in Italy. AIPO TB Study Group. Bull World Health Organ. 1999;77(6):467–76.
79. Mahendradhata Y, et al. The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogjakarta, Indonesia. Am J Trop Med Hyg. 2010;82(6):1131–9.
80. Prado TN, et al. Cost-effectiveness of community health worker versus home-based guardians for directly observed treatment of tuberculosis in Vitoria, Espirito Santo State, Brazil. Cad Saude Publica. 2011;27(5):944–52.
81. Costa JG, et al. Tuberculosis in Salvador, Brazil: costs to health system and families. Rev Saude Publica. 2005;39(1):122–8.
82. John KR, et al. Costs incurred by patients with pulmonary tuberculosis in rural India. Int J Tuberc Lung Dis. 2009;13(10):1281–7.
83. Muniyandi M, et al. A comparison of costs to patients with tuberculosis treated in a DOTS programme with those in a non-DOTS programme in South India. J Health Manag. 2008;10(1):9–24.
84. Datiko DG, Lindtjorn B. Cost and cost-effectiveness of smear-positive tuberculosis treatment by Health Extension Workers in Southern Ethiopia: a community randomized trial. PLoS One. 2010;5(2):e9158.
85. Wandwalo E, Robberstad B, Morkve O. Cost and cost-effectiveness of community based and health facility based directly observed treatment of tuberculosis in Dar es Salaam, Tanzania. Cost Eff Resour Alloc. 2005;3:6.
86. Rouzier VA, et al. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, Ecuador. Int J Tuberc Lung Dis. 2010;14(10):1316–22.
87. Diel R, et al. Cost of multi drug resistance tuberculosis in Germany. Respir Med. 2014;108(11):1677–87.
88. Wurtz R, White WD. The cost of tuberculosis: utilization and estimated charges for the diagnosis and treatment of tuberculosis in a public health system. Int J Tuberc Lung Dis. 1999;3(5):382–7.
89. Maponga CC, Nazerali H, Mungwindri C, Wingwirl M. Cost implications of the tuberculosis/HIV co-epidemic and drug treatment of tuberculosis in Zimbabwe. J Soc Adm Pharm. 1996;13(1):20–9.
90. DeRiemer K, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet. 2005;365(9466):1239–45.
91. Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc Biol Sci. 2001;268(1462):45–52.
92. Palmer CS, et al. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis. J Public Health Manag Pract. 1998;4(3):1–13.
93. Marchand R, Tousignant P, Chang H. Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly. Int J Epidemiol. 1999;28(3):563–70.
94. MacIntyre CR, Plant AJ, Hendrie D. Shifting the balance between in-patient and out-patient care for tuberculosis results in economic savings. Int J Tuberc Lung Dis. 2001;5(3):266–71.
95. Tu HZ, et al. Combination of molecular assay and clinical evaluation for early confirmation of tuberculosis cases. Clin Microbiol Infect. 2011;17(5):712–4.
96. Ruiz MG, Nunez LR, Lezama MAS, Valle FC. Costos de atencipn de la tuberculosis: caso del instituto nacional de enfermedadaes respiratorias (INER). Rev Instituto Nac Enferm Respir. 2003:16(4):219–25.
97. Sinanovic E, Kumaranayake L. Financing and cost-effectiveness analysis of public–private partnerships: provision of tuberculosis treatment in South Africa. Cost Eff Resour Alloc. 2006;4:11.
98. Jackson S, et al. Poverty and the economic effects of TB in rural China. Int J Tuberc Lung Dis. 2006;10(10):1104–10.
99. Liu X, et al. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. Trop Med Int Health. 2007;12(12):1464–71.
100. Guzman-Montes GY, Ovalles RH, Leniado-Laborin R. Indirect patient expenses for antituberulosis treatment in Tijuana, Mexico: is treatment really free? J Infect Dev Ctries. 2009;3(10):778–82.
101. Samandari T, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
102. Nieto E, et al. Cost-effectiveness of an alternative tuberculosis treatment: home-based guardian monitoring of patients. Rev Panam Salud Publica. 2012;32(3):178–84.
103. Zou G, et al. Incremental cost-effectiveness of improving treatment results among migrant tuberculosis patients in Shanghai. Int J Tuberc Lung Dis. 2013;17(8):1056–64.
104. Wei X, et al. China tuberculosis policy at crucial crossroads: Comparing the practice of different hospital and tuberculosis control collaboration models using survey data. PLoS One. 2014:9(3):e90596.
105. Foster N, et al. The economic burden of TB diagnosis and treatment in South Africa. Soci Sci Med. 2015;130:42–50.
106. Rajeswari R, et al. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis. 1999;3(10):869–77.
107. Peabody JW, et al. The burden of disease, economic costs and clinical consequences of tuberculosis in the Philippines. Health Policy Plan. 2005;20(6):347–53.
108. Aspler A, et al. Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis. 2008;12(8):928–35.
109. Mauch V, et al. Assessing access barriers to tuberculosis care with the tool to estimate patients’ costs: pilot results from two districts in Kenya. BMC Public Health. 2011;11:43.
110. Umar NA, et al. Direct costs of pulmonary tuberculosis among patients receiving treatment in Bauchi State, Nigeria. Int J Tuberc Lung Dis. 2012;16(6):835–40.
111. Gibson N, Boillot F, Jalloh H. The cost of tuberculosis to patients in Sierra Leone’s war zone. Int J Tuberc Lung Dis. 1998;2(9):726–31.
112. Karki DK, et al. Costs of a successful public-private partnership for TB control in an urban setting in Nepal. BMC public health. 2007;7:84.
113. Mirzoev TN, et al. Community-based DOTS and family member DOTS for TB control in Nepal: costs and cost-effectiveness. Cost Eff Resour Alloc. 2008;6:20.
114. Laokri S, et al. Patients are paying too much for tuberculosis: a direct cost-burden evaluation in Burkina Faso. PLoS One. 2013;8(2):e56752.
115. Laokri S, et al. A care pathway analysis of tuberculosis patients in Benin: highlights on direct costs and critical stages for an evidence-based decision-making. PLoS One. 2014:9(5):e96912.